FGFR3 and neoplasm: In cell line models expressing mutants FGFR2 W290C and S320C, or FGFR3 R248C and S249C, infigratinib was able to reduce the transformation properties of these cells in anchorage-independent conditions and reduce tumour volume in xenograft mouse models [28].